AMH Specific Neutra™ Antibody Products

Are you challenged by inconsistent AMH detection, limited therapeutic targeting, or complex assay validation? Creative Biolabs' AMH-specific Neutra™ antibody products leverage proprietary epitope engineering and high-affinity validation to provide unparalleled specificity, allowing for precise detection, functional inhibition, and efficient therapeutic development.

Introduction to AMH

Anti-Müllerian Hormone (AMH), a glycoprotein member of the TGF-β superfamily, governs critical biological processes such as sexual differentiation in males and follicular maturation in females. Produced by granulosa cells in ovarian follicles and Sertoli cells in testes, AMH levels serve as biomarkers for ovarian reserve and disorders like polycystic ovary syndrome (PCOS).

Fig.1 The utility of the assessment of AMH concentration in the different fields of medicine.¹

• Structural Insights

AMH exists as a dimeric protein composed of a pro-region and a mature domain. Proteolytic cleavage releases the bioactive C-terminal ligand, which binds to AMH type II receptors (AMHRII). Structural studies reveal conserved cysteine residues stabilizing disulfide bonds essential for receptor interaction. Creative Biolabs' antibodies target conformational epitopes within the mature domain, ensuring potent neutralization.

• Signaling Pathways

AMH signaling activates SMAD1/5/8 via AMHRII and ALK2/3 kinases, regulating gene expression in reproductive tissues. Dysregulation contributes to pathologies such as granulosa cell tumors and diminished ovarian reserve. Neutralizing AMH disrupts these pathways, offering therapeutic potential in cancer and fertility disorders.

Fig.2 Schematic representation of AMH signaling pathways.¹

• Disease Relevance

Elevated AMH correlates with PCOS and ovarian hyperstimulation syndrome, while low levels predict premature ovarian insufficiency. In oncology, AMH overexpression in granulosa cell tumors drives proliferation. Targeting AMH with neutralizing antibodies enables precise modulation of these conditions.

Applications of AMH Neutralizing Antibodies

• Diagnostic Assays for Ovarian Reserve Assessment

AMH levels are pivotal in evaluating ovarian reserve and predicting IVF outcomes. Our antibodies enable ultrasensitive quantification in serum, overcoming interference from binding proteins.

• Therapeutic Targeting in Reproductive Disorders

In PCOS, neutralizing AMH reduces excessive follicular recruitment, restoring folliculogenesis balance. Preclinical models demonstrate efficacy in mitigating hyperandrogenism and metabolic dysfunction.

• Oncology Research and Therapy

AMH-neutralizing antibodies inhibit granulosa cell tumor growth by blocking autocrine signaling. Combinatorial use with chemotherapies enhances tumor regression in xenograft models.

• Fertility Preservation Strategies

By transiently suppressing AMH, these antibodies extend primordial follicle dormancy, offering novel approaches to preserve fertility during chemotherapy.

• Mechanistic Studies in Developmental Biology

Antibodies allow for exact deconstruction of AMH's role in Müllerian duct regression and testicular development, advancing understanding of intersex disorders.

AMH-Specific Antibodies

Creative Biolabs offers AMH-specific Neutra™ antibody products, which are engineered for precision and reliability, validated across research and preclinical models. Our AMH-Specific Antibodies are rigorously validated for applications including ELISA, immunohistochemistry, and functional neutralization. Key advantages:

- High Specificity: Engineered to avoid cross-reactivity with TGF-β family paralogs.

- Functional Neutralization: Block AMH-AMHRII binding, validated in cell-based bioassays.

- Thermostability: Optimized for long-term storage while maintaining affinity.

These antibodies are indispensable for researchers developing AMH-targeted therapies or diagnostic assays.

Contact our team to explore custom solutions for your AMH-focused projects.

REFERENCE

1. Gowkielewicz, Marek, et al. "Anti-Müllerian hormone: biology and role in endocrinology and cancers." Frontiers in Endocrinology 15 (2024): 1468364. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fendo.2024.1468364